Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 248-655-3 | CAS number: 27776-21-2
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics, other
- Type of information:
- other: Assessment based on available physico-chemical data
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Assessment based on available physico-chemical data
Data source
Reference
- Reference Type:
- other company data
- Title:
- Unnamed
- Year:
- 2 016
- Report date:
- 2016
Materials and methods
- Objective of study:
- absorption
- distribution
- excretion
- metabolism
Test guideline
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- Assessment based on available physico-chemical data
- GLP compliance:
- no
Test material
- Reference substance name:
- 2,2'-Azobis[2-(2-imidazolin-2-yl)propane] dihydrochloride
- Cas Number:
- 27776-21-2
- IUPAC Name:
- 2,2'-Azobis[2-(2-imidazolin-2-yl)propane] dihydrochloride
- Test material form:
- solid: particulate/powder
- Remarks:
- particle size not specified
Constituent 1
Results and discussion
Main ADME resultsopen allclose all
- Type:
- absorption
- Results:
- see "any other information on results incl. tables" section
- Type:
- distribution
- Results:
- see "any other information on results incl. tables" section
- Type:
- metabolism
- Results:
- see "any other information on results incl. tables" section
- Type:
- excretion
- Results:
- see "any other information on results incl. tables" section
Any other information on results incl. tables
Absorption:
Based on above data the substance may not be absorbed through the skin in relevant amounts as the Log POWis below the lower threshold of -1 (molecular weight < 500 g/Mol, -1 < log POW< 4, see EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRETORATE-GENERAL: Guidance Document on Dermal Absorpiton Sanco/222/2000 rev. 7 19 March 2004).
For exposure assessments a default value of 10 % of absorption after dermal exposure may be appropriate.
The uptake after direct inhalation of the solid substance may be of significant relevance due to findings in an acute inhalation toxicity study. Additionally the substance is marketed as powder and a granulometric studies is not available. For Risk assessment purposes a value of 100 % absorption after inhalation may be appropriate. Uptake by inhalation after evaporation is unlikely, the substance is a solid at room temperature decomposes upon heating together with a very low vapour pressure.
The absorption after oral ingestion cannot be calculated due to lack of data; by default an absorption of 100 % may be appropriate, until specific data will be available, although such a high absorption is rather unlikely.
Distribution:
The substance is highly hydrophilic therefore distribution to lipophilic body tissues is unlikely. The limited stability together with the high hydrophilicity likely excludes bio accumulation. There are no further information available therefore a more detailed description is futile.
Metabolism and Excretion:
Taking into account the structural elements of the formula it follows that the unchanged substance is a substrate for Phase I Enzymes, especially the imidazole residues. Due to the low stability of the substance, it is likely that decomposition occurs before the substance reaches the metabolic organs. However, the imidazole residues is not primarly effected by the decomposition mechanism (radical formation and release of molecular nitrogen from the central azo Group).
Subsequent to decomposition and Phase I metabolism, the different Phase-II aducts can be formed. There is no indication whether a Glutathion-, Sulphate-, Acetate- or Glucuronate adduct is favoured.
The high water solubility of the substance indicates urinary excretion as the most relevant way of excretion for the unchanged substance.
Another relevant pathway for exretion may be by feces, especially for the fraction, which has not been absorbed in the gastrointestinal tract after oral uptake.
Excretion by exhalation does not seem to be relevant.
Applicant's summary and conclusion
- Conclusions:
- An assessment based on available physico-chemical data is performed.
The relevant results are taken for risk assessment purposes:
dermal absorption: 10%
inhalative absorption: 100%
oral absorption: 100 %
Bioaccumulation: unlikely
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
